Concepedia

Sandra Hadl

SH

Statistics

Publications

4

Citations

332

H-Index

4

Active since

2023

Affiliations

Valneva (Austria)(Current)

University of Applied Sciences Burgenland

Sandra Hadl is an author at Valneva (Austria) specializing in immunology, vaccine-preventable diseases, and vaccination.

Publications per year

2023–2024

4

Publications

4

Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial

Martina Schneider, Marivic Narciso-Abraham, Sandra Hadl et al. · The Lancet · 2023 · 223 citations · Full text

, , +17

Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study

Robert P. McMahon, Sebastian Toepfer, Natascha Sattler et al. · The Lancet Infectious Diseases · 2024 · 41 citations

, , +11

A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults

Robert P. McMahon, Ulrike Fuchs, Martina Schneider et al. · Journal of Travel Medicine · 2023 · 36 citations · Full text

, , +15

Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents

Vera Buerger, Sandra Hadl, Martina Schneider et al. · The Lancet Infectious Diseases · 2024 · 32 citations

, , +14

1–4 of 4